These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

896 related articles for article (PubMed ID: 27842901)

  • 1. Comparison of heparin, bivalirudin, and different glycoprotein IIb/IIIa inhibitor regimens for anticoagulation during percutaneous coronary intervention: A network meta-analysis.
    Lipinski MJ; Lee RC; Gaglia MA; Torguson R; Garcia-Garcia HM; Pichard AD; Satler LF; Waksman R
    Cardiovasc Revasc Med; 2016 Dec; 17(8):535-545. PubMed ID: 27842901
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bivalirudin versus heparin plus a glycoprotein IIb/IIIa inhibitor in patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention after clopidogrel pretreatment: pooled analysis from the ACUITY and ISAR-REACT 4 trials.
    Ndrepepa G; Neumann FJ; Deliargyris EN; Mehran R; Mehilli J; Ferenc M; Schulz S; Schömig A; Kastrati A; Stone GW
    Circ Cardiovasc Interv; 2012 Oct; 5(5):705-12. PubMed ID: 23048052
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized two-by-two comparison of high-dose bolus tirofiban versus abciximab and unfractionated heparin versus bivalirudin during percutaneous coronary revascularization and stent placement: the tirofiban evaluation of novel dosing versus abciximab with clopidogrel and inhibition of thrombin (TENACITY) study trial.
    Moliterno DJ;
    Catheter Cardiovasc Interv; 2011 Jun; 77(7):1001-9. PubMed ID: 21598351
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of timing of clopidogrel treatment on the efficacy and safety of bivalirudin in patients with non-ST-segment elevation acute coronary syndromes undergoing percutaneous coronary intervention: an analysis of the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial.
    Lincoff AM; Steinhubl SR; Manoukian SV; Chew D; Pollack CV; Feit F; Ware JH; Bertrand ME; Ohman EM; Desmet W; Cox DA; Mehran R; Stone GW;
    JACC Cardiovasc Interv; 2008 Dec; 1(6):639-48. PubMed ID: 19463378
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficiency and safety of bivalirudin in patients undergoing emergency percutaneous coronary intervention via radial access: A subgroup analysis from the bivalirudin in acute myocardial infarction versus heparin and GPI plus heparin trial.
    Wang H; Li Y; Cong H; Ding S; Liu B; Li L; Chen Y; Jia S; Jing Q; Zhao X; Liu H; Liang Z; Li J; Bao D; Han Y
    Catheter Cardiovasc Interv; 2017 Jun; 89(7):1157-1165. PubMed ID: 27677411
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a multicentre, randomised controlled trial.
    Valgimigli M; Frigoli E; Leonardi S; Vranckx P; Rothenbühler M; Tebaldi M; Varbella F; Calabrò P; Garducci S; Rubartelli P; Briguori C; Andó G; Ferrario M; Limbruno U; Garbo R; Sganzerla P; Russo F; Nazzaro M; Lupi A; Cortese B; Ausiello A; Ierna S; Esposito G; Ferrante G; Santarelli A; Sardella G; de Cesare N; Tosi P; van 't Hof A; Omerovic E; Brugaletta S; Windecker S; Heg D; Jüni P;
    Lancet; 2018 Sep; 392(10150):835-848. PubMed ID: 30153988
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of a prolonged bivalirudin infusion after urgent and complex percutaneous coronary interventions: a descriptive study.
    Cortese B; Micheli A; Picchi A; Bandinelli L; Brizi MG; Severi S; Limbruno U
    Coron Artery Dis; 2009 Aug; 20(5):348-53. PubMed ID: 19543084
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comprehensive meta-analysis of safety and efficacy of bivalirudin versus heparin with or without routine glycoprotein IIb/IIIa inhibitors in patients with acute coronary syndrome.
    Navarese EP; Schulze V; Andreotti F; Kowalewski M; Kołodziejczak M; Kandzari DE; Rassaf T; Gorny B; Brockmeyer M; Meyer C; Berti S; Kubica J; Kelm M; Valgimigli M
    JACC Cardiovasc Interv; 2015 Jan; 8(1 Pt B):201-213. PubMed ID: 25616926
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anticoagulant therapy during primary percutaneous coronary intervention for acute myocardial infarction: a meta-analysis of randomized trials in the era of stents and P2Y12 inhibitors.
    Bangalore S; Toklu B; Kotwal A; Volodarskiy A; Sharma S; Kirtane AJ; Feit F
    BMJ; 2014 Nov; 349():g6419. PubMed ID: 25389143
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heparin is Not Inferior to Bivalirudin in Percutaneous Coronary Intervention-Focusing on the Effect of Glycoprotein IIb/IIIa Inhibitor Use: A Meta-Analysis.
    Huang FY; Huang BT; Peng Y; Liu W; Zhao ZG; Wang PJ; Zuo ZL; Zhang C; Liao YB; Luo XL; Meng QT; Chen C; Huang KS; Chai H; Li Q; Chen M; Zhu Y
    Angiology; 2015 Oct; 66(9):845-55. PubMed ID: 25635117
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative cost-effectiveness of anticoagulation with bivalirudin or heparin with and without a glycoprotein IIb/IIIa-receptor inhibitor in patients undergoing percutaneous coronary intervention in Sweden: a decision-analytic model.
    Borg S; Persson U; Allikmets K; Ericsson K
    Clin Ther; 2006 Nov; 28(11):1947-59. PubMed ID: 17213015
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of anti-thrombotic strategies using Bivalirudin, Heparin plus Glycoprotein IIb/IIIa inhibitors and Unfractionated Heparin Monotherapy for patients undergoing percutaneous coronary intervention - A single centre observational study.
    Kaul U; Dua A; Sethi AK; Arambam P; Seth A
    Indian Heart J; 2015; 67(4):311-7. PubMed ID: 26304562
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of bivalirudin in patients receiving clopidogrel therapy after diagnostic angiography for percutaneous coronary intervention in acute coronary syndromes.
    Feldman DN; Minutello RM; Bergman G; Moussa I; Wong SC
    Catheter Cardiovasc Interv; 2010 Oct; 76(4):513-24. PubMed ID: 20882655
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bivalirudin in patients undergoing primary percutaneous coronary intervention for acute ST-elevation myocardial infarction: outcomes in a large real-world population.
    Shelton R; Eftychiou C; Somers K; Liu A; Burton-Wood N; Anderson M; Makri L; Blaxill J; McLenachan J; Wheatcroft S; Greenwood J; Blackman D
    EuroIntervention; 2013 May; 9(1):118-24. PubMed ID: 23410540
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acute stent thrombosis after primary percutaneous coronary intervention: insights from the EUROMAX trial (European Ambulance Acute Coronary Syndrome Angiography).
    Clemmensen P; Wiberg S; Van't Hof A; Deliargyris EN; Coste P; Ten Berg J; Cavallini C; Hamon M; Dudek D; Zeymer U; Tabone X; Kristensen SD; Bernstein D; Anthopoulos P; Prats J; Steg PG
    JACC Cardiovasc Interv; 2015 Jan; 8(1 Pt B):214-220. PubMed ID: 25616927
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bivalirudin versus heparin with or without glycoprotein IIb/IIIa inhibitors in patients with STEMI undergoing primary percutaneous coronary intervention: pooled patient-level analysis from the HORIZONS-AMI and EUROMAX trials.
    Stone GW; Mehran R; Goldstein P; Witzenbichler B; Van't Hof A; Guagliumi G; Hamm CW; Généreux P; Clemmensen P; Pocock SJ; Gersh BJ; Bernstein D; Deliargyris EN; Steg PG
    J Am Coll Cardiol; 2015 Jan; 65(1):27-38. PubMed ID: 25572507
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Utilization of anticoagulants and outcomes in STEMI patients undergoing PPCI in the US hospitals: Bivalirudin, heparin plus GPI or heparin alone?
    Plent S; Mitchell M; Fan W; Werner R
    Hosp Pract (1995); 2015; 43(3):164-71. PubMed ID: 26190670
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of bivalirudin with glycoprotein IIb/IIIa for high-risk percutaneous coronary intervention.
    Deshpande NV; Pratiti R; Admane P; Mukherjee D; Mardikar HM
    Indian Heart J; 2012; 64(5):444-8. PubMed ID: 23102380
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bleeding risk and outcomes of Bivalirudin versus Glycoprotein IIb/IIIa inhibitors with targeted low-dose unfractionated Heparin in patients having percutaneous coronary intervention for either stable or unstable angina pectoris.
    Steinberg DH; Shah P; Kinnaird T; Pinto Slottow TL; Roy PK; Okabe T; Bonello L; de Labriolle A; Smith KA; Torguson R; Xue Z; Suddath WO; Kent KM; Satler LF; Pichard AD; Lindsay J; Waksman R
    Am J Cardiol; 2008 Jul; 102(2):160-4. PubMed ID: 18602514
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of bivalirudin with heparin versus abciximab with heparin for primary percutaneous coronary intervention in "Real World" practice.
    Showkathali R; Davies JR; Parker M; Taggu W; Tang KH; Clesham GJ; Gamma RA; Sayer JW; Aggarwal RK; Kelly PA
    Cardiovasc Revasc Med; 2013; 14(5):289-93. PubMed ID: 23972537
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 45.